Scalper1 News
Biotech Alder Biopharmaceuticals (ALDR) jumped to a new high above 51 Wednesday after a Credit Suisse analyst assumed coverage with an outperform rating. Analyst Vamil Divan wrote that Alder’s lead drug candidate ALD-403, a CGRP antibody for migraine, “has the potential to be a best-in-class asset given its strong efficacy and long duration of response, positioning it as potentially a once-quarterly treatment.” Divan wrote that competing Scalper1 News
Scalper1 News